5 completed, 2 terminated. 7 Phase 2, 3 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 5, Terminated 2 |
| Phase 3 | 3 | Completed 3 |
| Phase 1 | 1 | Completed 1 |
Follow Inappropriate ADH Syndrome: new trials by email Literature Review of Inappropriate ADH Syndrome trials Research Report on Inappropriate ADH Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Urea for Chronic Hyponatremia Urea - Hyponatremia, Inappropriate ADH Syndrome | Phase 2 | Terminated | Helbert Rondon Berrios, MD, MS | 2 | 2021-12-28 | 2024-05-20 |
| Effects of the SGLT2-inhibitor Empagliflozin on Patients With Chronic SIADH - the SANDx Study Empagliflozin 25mg, Placebo - SIAD - Syndrome of Inappropriate Antidiuresis, Hyponatremia | Phase 2 / Phase 3 | Completed | University Hospital, Basel, Switzerland | 17 | 2017-12-15 | 2021-12-13 |
| Effects of the SGLT2-inhibitor Empagliflozin on Patients With SIADH - the SAND Study Empagliflozin, Placebo - SIADH | Phase 2 / Phase 3 | Completed | University Hospital, Basel, Switzerland | 88 | 2016-09-05 | 2019-06-13 |
| Effects of Empagliflozin an SGLT2-Inhibitor on Healthy Volunteers With Induced Hypotonic Hyponatremia - the DIVE Study Induced hypotonic hyponatremia - SIAD model, Empagliflozin 25mg Tbl, Placebo P-Tablet - Inappropriate ADH Syndrome | Phase 2 / Phase 3 | Completed | University Hospital, Basel, Switzerland | 15 | 2016-03-01 | 2016-08-10 |
| A PK Study of 3 Dosages of Tolvaptan in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) tolvaptan - Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) | Phase 1 / Phase 2 | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | 30 | 2013-11-01 | 2016-05-16 |
| Tolvaptan for In-hospital Hyponatremia Tolvaptan, Standard therapy - Hyponatremia | Phase 2 | Terminated | Mario Negri Institute for Pharmacological Research | 3 | 2011-06-01 | 2016-12-15 |
| Efficacy of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion satavaptan (SR121463B) - Syndrome of Inappropriate ADH (SIADH) Secretion, Hyponatremia | Phase 2 | Completed | Sanofi | 35 | 2001-06-01 | 2008-06-17 |
Hyponatremia (6) · Diabetes Insipidus (1)
Brain Diseases (7) · Central Nervous System Diseases (7) · Endocrine System Diseases (7) · Hypothalamic Diseases (7) · Metabolic Diseases (7) · Nervous System Diseases (7) · Nutritional and Metabolic Diseases (7) · Pituitary Diseases (7) · Water-Electrolyte Imbalance (7) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Kidney Diseases (1) · Male Urogenital Diseases (1) · Urogenital Diseases (1) · Urologic Diseases (1)
empagliflozin (3) · Tolvaptan (2) · Standard of Care (1) · Tablets (1) · Urea (1) · satavaptan (1)
University Hospital, Basel, Switzerland (3) · Helbert Rondon Berrios, MD, MS (1) · Mario Negri Institute for Pharmacological Research (1) · Otsuka Pharmaceutical Development & Commercialization, Inc. (1) · Sanofi (1)
Switzerland (3) · Germany (2) · Hungary (2) · Belgium (1) · Czechia (1) · Denmark (1) · France (1) · Italy (1) · Spain (1) · Sweden (1) · United Kingdom (1) · United States (1)
Helbert Rondon Berrios, MD. MS (1) · Mirjam Christ-Crain, Prof. (1) · Mirjam Christ-Crain, Prof. Dr. MD (1) · Mirjam Christ-Crain, Prof., MD (1)
PMID 34412521, PMID 36396331, PMID 37098131, PMID 42522233
2015 (1), 2017 (1), R21DK122023 (1)